Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.
about
Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolatesA Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-AnalysisRising to the challenge: new therapies for tuberculosisMechanisms of Pyrazinamide Action and ResistancePyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in GeorgiaRevisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.Tenosynovitis caused by a novel nontuberculous Mycobacterium species initially misidentified as a member of the Mycobacterium tuberculosis complex.Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, ChinaGenetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009Genotypic characterization of drug resistant Mycobacterium tuberculosis in Quebec, 2002-2012.Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.Role of rpsA gene sequencing in diagnosis of pyrazinamide resistanceMulticenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in ChinaRole of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China.Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010.'Z(S)-MDR-TB' versus 'Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibilityEvaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment.Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA.A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide.Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum.Characterization of Mycobacterium orygis.Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation.Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing.A Rapid Growth-Independent Antibiotic Resistance Detection Test by SYBR Green/Propidium Iodide Viability Assay.
P2860
Q27004697-C117AFA0-011A-4B9E-9118-9587455D745DQ27011264-BF340963-CCBF-4D49-8636-2061546F7A02Q27011672-8C8F9606-99C8-4019-BB99-68E7F69021EEQ29304444-438D9985-09AE-4FCA-BB75-AB4113670B36Q33896434-457F6B53-22E0-4CC3-A56F-B964CA74AEE5Q34708437-B2D7C89F-0704-40D7-AB2A-C7E4F5C6D313Q35036334-CCF2D143-21D7-436C-9502-DAB8EE48D935Q35076847-C96C7680-BD6F-45A2-A354-7B539D9CD529Q35105829-A5389B2F-7E0F-42B9-9DC1-4710020CC9B3Q35743972-38BA4B6C-4924-4CAB-8135-252D6393108AQ36082638-1F8E40CD-0300-4468-ACFB-48295ABEB0FDQ36086220-D0CCBA2C-3456-4409-8E12-3991BFAF02CAQ36149564-F7B781DD-046C-4A82-A96F-6D42FAC2120DQ36174022-7F65AD98-BEAB-4915-A4EC-CA33014B2E57Q36506283-2431A2A5-B14A-42BD-B730-9C7EB7FBC43DQ37203722-8FF32285-03F2-4550-A0CC-CAE7A61BB386Q37546627-73639B7B-49A9-475E-9653-2E57644C8618Q37612926-37DD1E3C-0319-4C13-AC20-32C8D3DAF3C5Q38514218-22409B21-3087-43ED-91D3-01C6FAECA466Q38739933-8A262ADA-1C8F-4CA7-BE02-3C903DD6FE19Q40048055-63E6A1BB-2497-4FEF-B8C4-0D6BA0C95D5FQ41580259-72C33BE0-1B6D-4CB6-8B71-6DF6B3A982EAQ41701192-56DC83E3-7647-4F20-8D75-184ED16B7F09Q42127991-73A4DA11-523E-42AF-B06B-123E5F0E4A0DQ43171363-9908D9EE-7F72-4C9E-AF52-1FB50BFC06EAQ46765284-305A7755-5670-4289-B95F-06891EAAB7ADQ48362853-113FCF8D-A936-40E2-AC26-D002BD536E90Q50223757-654C7086-6166-4BD9-9B73-B368BCCA35CBQ55239147-D960BDA6-7EC2-4646-BD07-34F038897961
P2860
Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Validation of pncA gene sequen ...... tuberculosis to pyrazinamide.
@ast
Validation of pncA gene sequen ...... tuberculosis to pyrazinamide.
@en
type
label
Validation of pncA gene sequen ...... tuberculosis to pyrazinamide.
@ast
Validation of pncA gene sequen ...... tuberculosis to pyrazinamide.
@en
prefLabel
Validation of pncA gene sequen ...... tuberculosis to pyrazinamide.
@ast
Validation of pncA gene sequen ...... tuberculosis to pyrazinamide.
@en
P2093
P2860
P356
P1476
Validation of pncA gene sequen ...... tuberculosis to pyrazinamide.
@en
P2093
Arnout Mulder
Martin J Boeree
P N Richard Dekhuijzen
Sami O Simons
Tridia van der Laan
P2860
P304
P356
10.1128/JCM.05435-11
P407
P577
2011-11-16T00:00:00Z